A detailed history of Alpha Mark Advisors, LLC transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Alpha Mark Advisors, LLC holds 155 shares of VKTX stock, worth $8,151. This represents 0.0% of its overall portfolio holdings.

Number of Shares
155
Holding current value
$8,151
% of portfolio
0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 16, 2024

BUY
$49.84 - $70.47 $7,725 - $10,922
155 New
155 $10,000
Q3 2020

Nov 06, 2020

SELL
$5.73 - $8.11 $1,146 - $1,622
-200 Closed
0 $0
Q4 2018

Feb 06, 2019

SELL
$7.16 - $16.21 $1,432 - $3,242
-200 Reduced 50.0%
200 $2,000
Q3 2018

Nov 05, 2018

BUY
$9.7 - $19.65 $3,879 - $7,859
400 New
400 $7,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $4.03B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Alpha Mark Advisors, LLC Portfolio

Follow Alpha Mark Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpha Mark Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpha Mark Advisors, LLC with notifications on news.